Hematopoietic stem cell transplantation for chronic lymphocytic leukemia

Research output: Contribution to journalReview article

Abstract

PURPOSE OF REVIEW: Although hematopoietic stem cell transplantation (HSCT) is the treatment of choice for many aggressive hematologic malignancies, the role of HSCT in chronic lymphocytic leukemia (CLL) has remained controversial. Now in the era of improved conventional treatment and better prognostication of long-term outcome, a review of autologous and allogeneic HSCT in CLL treatment is warranted. RECENT FINDINGS: Despite an improved disease-free survival in some patients, multiple, prospective, randomized autologous HSCT CLL trials fail to demonstrate an overall survival benefit as compared to conventional therapy. Allogeneic bone marrow transplantation, although limited by donor availability, can successfully eradicate CLL with adverse prognostic features. In the older CLL patients, nonmyeloablative allogeneic transplants are better tolerated than myeloablative transplants. Nonmyeloablative allogeneic transplants are less effective in heavily diseased burdened patients. SUMMARY: Outside of a clinical protocol, autologous HSCT for CLL cannot be justified. Nonmyeloablative allogeneic transplantation should be considered in high-risk populations early in the disease process, when disease burden is most easily controlled. Alternative donor selection using haploidentical donors and posttransplantation cyclophosphamide has the potential to vastly increase the availability of curative therapy in CLL while retaining a low treatment-related toxicity.

Original languageEnglish (US)
Pages (from-to)176-181
Number of pages6
JournalCurrent opinion in oncology
Volume24
Issue number2
DOIs
StatePublished - Mar 1 2012

    Fingerprint

Keywords

  • allogeneic
  • autologous
  • chronic lymphocytic leukemia
  • hematopoietic stem cell transplantation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this